Nisa Investment Advisors
TLX

Nisa Investment Advisors’s Telix Pharmaceuticals TLX Stock Holding History

Nisa Investment Advisors’s Portfolio TLX Stock Details TLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01K Buy
88
+23
+35% +$234 ﹤0.01% 2848
2026
Q1 		$622 Buy
+65
New +$495 ﹤0.01% 2829

Other funds holding TLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return
PIC
Portland Investment Counsel Burlington, Ontario, Canada $358M AUM 26.37% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
IWC
Integrated Wealth Concepts Waltham, Massachusetts $15.3B AUM 25.33% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Nisa Investment Advisors's TLX Position: Q2 2026 in Review

Nisa Investment Advisors increased its Telix Pharmaceuticals (TLX) stake by 35% in Q2 2026, buying an estimated $234 and bringing the position to 88 shares worth $1.01K. The position accounts for ﹤0.01% of the portfolio, ranked #2848.

Nisa Investment Advisors first reported a position in TLX in Q1 2026 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold TLX as of Q2 2026.

  • Nisa Investment Advisors held 88 shares of Telix Pharmaceuticals worth $1.01K as of Q2 2026.
  • Nisa Investment Advisors bought 23 Telix Pharmaceuticals shares in Q2 2026, an estimated $234.
  • Telix Pharmaceuticals made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q2 2026, its #2848 holding.
  • Nisa Investment Advisors first reported a position in Telix Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held Telix Pharmaceuticals as of Q2 2026.

Based on Nisa Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.